ES529170A0 - El agente antitumoral rebecamicina - Google Patents

El agente antitumoral rebecamicina

Info

Publication number
ES529170A0
ES529170A0 ES529170A ES529170A ES529170A0 ES 529170 A0 ES529170 A0 ES 529170A0 ES 529170 A ES529170 A ES 529170A ES 529170 A ES529170 A ES 529170A ES 529170 A0 ES529170 A0 ES 529170A0
Authority
ES
Spain
Prior art keywords
rebecamicina
antitumoral agent
rebeccamycin
atcc
fermentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES529170A
Other languages
English (en)
Other versions
ES8607396A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of ES8607396A1 publication Critical patent/ES8607396A1/es
Publication of ES529170A0 publication Critical patent/ES529170A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
ES529170A 1983-01-28 1984-01-26 El agente antitumoral rebecamicina Expired ES8607396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/461,817 US4487925A (en) 1983-01-28 1983-01-28 Rebeccamycin and process for its preparation

Publications (2)

Publication Number Publication Date
ES8607396A1 ES8607396A1 (es) 1986-05-16
ES529170A0 true ES529170A0 (es) 1986-05-16

Family

ID=23834041

Family Applications (1)

Application Number Title Priority Date Filing Date
ES529170A Expired ES8607396A1 (es) 1983-01-28 1984-01-26 El agente antitumoral rebecamicina

Country Status (15)

Country Link
US (1) US4487925A (es)
EP (1) EP0115350B1 (es)
JP (1) JPS59141597A (es)
KR (1) KR910002856B1 (es)
AT (1) ATE36540T1 (es)
AU (1) AU564256B2 (es)
CA (1) CA1220149A (es)
DE (1) DE3473459D1 (es)
DK (1) DK160429C (es)
ES (1) ES8607396A1 (es)
FI (1) FI77264C (es)
GR (1) GR81748B (es)
IE (1) IE56651B1 (es)
PT (1) PT78019B (es)
ZA (1) ZA84582B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524145A (en) * 1984-09-04 1985-06-18 Bristol-Myers Company 4'-Deschlororebeccamycin pharmaceutical composition and method of use
US4567143A (en) * 1984-09-04 1986-01-28 Bristol-Myers Company Process for preparing 4'-deschlororebeccamycin
US4743594A (en) * 1984-09-17 1988-05-10 Schering Corporation Antibiotic, antitumor compounds and their use
US4764510A (en) * 1986-04-11 1988-08-16 Eli Lilly And Company Antibiotic A42125 and process for its production
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
JPH0725787B2 (ja) * 1990-03-06 1995-03-22 ブリストル−マイヤーズ スクイブ カンパニー 臭化物前駆物質物質供給によるレベカマイシン類似体
US5344823A (en) * 1990-03-06 1994-09-06 Bristol-Myers Squibb Company Antitumor antibiotic BMY-41219
US5158938A (en) * 1990-03-06 1992-10-27 Bristol-Myers Squibb Company Rebeccamycin
IL97233A (en) * 1990-03-06 1995-03-30 Bristol Myers Squibb Co Rebeccamycin analogs, their production and pharmaceutical compositions containing them
US5478813A (en) * 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
CA2130836A1 (en) * 1992-03-20 1993-09-30 Martin J. Slater Further indole derivatives with antiviral activity
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
JP2004534006A (ja) 2001-03-22 2004-11-11 ブリストル−マイヤーズ スクイブ カンパニー インドロピロロカルバゾール化合物のトポイソメラーゼi選択的細胞毒シュガー誘導体
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
FR2956934B1 (fr) 2010-02-26 2012-09-28 Blink E Procede et dispositif d'emission/reception de signaux electromagnetiques recus/emis sur une ou plusieurs premieres bandes de frequences.
FR2990315B1 (fr) 2012-05-04 2014-06-13 Blink E Procede de transmission d'informations entre une unite emettrice et une unite receptrice

Also Published As

Publication number Publication date
JPH0452280B2 (es) 1992-08-21
AU2372084A (en) 1984-08-02
AU564256B2 (en) 1987-08-06
ATE36540T1 (de) 1988-09-15
US4487925A (en) 1984-12-11
EP0115350B1 (en) 1988-08-17
ZA84582B (en) 1984-09-26
GR81748B (es) 1984-12-12
EP0115350A2 (en) 1984-08-08
DE3473459D1 (en) 1988-09-22
EP0115350A3 (en) 1985-09-18
PT78019B (en) 1986-06-18
IE56651B1 (en) 1991-10-23
FI77264B (fi) 1988-10-31
IE840201L (en) 1984-07-28
ES8607396A1 (es) 1986-05-16
KR840007257A (ko) 1984-12-06
KR910002856B1 (ko) 1991-05-06
DK160429C (da) 1991-08-19
FI840301A0 (fi) 1984-01-25
DK35684D0 (da) 1984-01-26
FI77264C (fi) 1989-02-10
CA1220149A (en) 1987-04-07
DK35684A (da) 1984-07-29
FI840301L (fi) 1984-07-29
PT78019A (en) 1984-02-01
JPS59141597A (ja) 1984-08-14
DK160429B (da) 1991-03-11

Similar Documents

Publication Publication Date Title
DK35684A (da) Antitumor-midler
MY103388A (en) Azithromycin and derivatives as antiprotozoal agents
GB1534823A (en) Dental chairs or like patient supporting devices
DK0751959T3 (da) Modificerede polypeptider med forøget biologisk aktivitet
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
MY110664A (en) Protein c derivatives
AU4421585A (en) Potent thymopentin analogs
ES8706443A1 (es) Un procedimiento para preparar una solucion parenteral de activador de plasminogeno de tejido (t-pa)
MY103665A (en) Anthracycline glycosides
SE7704194L (sv) Antibiotiska foreningar
GB1508674A (en) Bottom-feed stacker assembly
SG18792G (en) Drug preparations of reduced toxicity
AU6311386A (en) Appetite moderating and anti-gastritis conposition
AU558614B2 (en) Modified microorganism to produce interferon like activity
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DE59005128D1 (de) t-PA pro STABILISIERUNG.
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
AU8640091A (en) Human interferon-gamma4-134, functional equivalents thereof and methods of using and compositions employing these materials
NZ184320A (en) Neoviridogriseins 1,iiandiii from the culture of streptomyces sp' atcc 31289
ES8502729A1 (es) "un procedimiento para producir el complejo antibiotico m 9226"
ES2005159A6 (es) Procedimiento para diagnostico y seguimiento de hepatopatias mediante determinacion de factor de crecimiento hepatico en plasma yno suero sanguineo.
JPS5524150A (en) Anti-malignant-tumor agent
FI841240A0 (fi) Foerbaettringar i makrolidantibiotika.
GB1464401A (en) Aminoglycosides
GR852224B (es)